We use cookies to measure traffic and show relevant ads. By clicking Accept you agree to our use of analytics and advertising cookies.
NEJM 期刊发布了药物 VERVE-102 的数据：单次 CRISPR 注射（碱基编辑）可将 LDL 降低 62%，持续 18 个月且无严重副作用。了解这种革命性疗法的详情。
